TW200528092A - Multiparticulate o-desmethylvenlafaxine salts and uses thereof - Google Patents

Multiparticulate o-desmethylvenlafaxine salts and uses thereof Download PDF

Info

Publication number
TW200528092A
TW200528092A TW094102533A TW94102533A TW200528092A TW 200528092 A TW200528092 A TW 200528092A TW 094102533 A TW094102533 A TW 094102533A TW 94102533 A TW94102533 A TW 94102533A TW 200528092 A TW200528092 A TW 200528092A
Authority
TW
Taiwan
Prior art keywords
patent application
scope
item
formulation
odv
Prior art date
Application number
TW094102533A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher Richard Diorio
Syed M Shah
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200528092A publication Critical patent/TW200528092A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094102533A 2004-02-06 2005-01-27 Multiparticulate o-desmethylvenlafaxine salts and uses thereof TW200528092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54238404P 2004-02-06 2004-02-06

Publications (1)

Publication Number Publication Date
TW200528092A true TW200528092A (en) 2005-09-01

Family

ID=34860300

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094102533A TW200528092A (en) 2004-02-06 2005-01-27 Multiparticulate o-desmethylvenlafaxine salts and uses thereof

Country Status (21)

Country Link
US (1) US20050175698A1 (https=)
EP (2) EP2052717A1 (https=)
JP (1) JP2007520553A (https=)
KR (1) KR20060132891A (https=)
CN (1) CN1917860A (https=)
AR (1) AR050230A1 (https=)
AU (1) AU2005212166A1 (https=)
BR (1) BRPI0507372A (https=)
CA (1) CA2554559A1 (https=)
CR (1) CR8535A (https=)
EC (1) ECSP066827A (https=)
IL (1) IL177052A0 (https=)
NO (1) NO20063963L (https=)
PA (1) PA8622601A1 (https=)
PE (1) PE20050771A1 (https=)
RU (1) RU2006127437A (https=)
SG (1) SG149894A1 (https=)
SV (1) SV2005002008A (https=)
TW (1) TW200528092A (https=)
WO (1) WO2005077340A1 (https=)
ZA (1) ZA200606526B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2002250058B2 (en) 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US20070014859A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
US20070015828A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110046231A1 (en) * 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
WO2013164559A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081496A (en) * 1959-10-15 1963-03-19 John F Moore Method of forming flexible sheets of cured foamed rubber
AT294000B (de) * 1965-01-11 1971-11-10 Diersch & Schroeder Verfahren zur Herstellung von Teppichen oder Läufern
US3885257A (en) * 1972-10-30 1975-05-27 Evans Ronald J P Pressure controlled resilient supporting structure
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4603445A (en) * 1983-09-09 1986-08-05 Span-America Medical Systems, Inc. Support pad and method of manufacture
US5099627A (en) * 1990-09-28 1992-03-31 Benjamin Obdyke Incorporated Ventilated roof construction and method
US5203703A (en) * 1991-08-27 1993-04-20 Schneiderman Marc J Deglutition training method and apparatus
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6162309A (en) * 1998-04-21 2000-12-19 Burlington Industries, Inc. Reinforced foam backed carpet
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6863972B2 (en) * 2001-01-09 2005-03-08 Crane Plastics Company Llc Synthetic wood component having a foamed polymer backing
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
US20030152741A1 (en) * 2002-02-05 2003-08-14 Robbins Jeffrey L. Patterned polyurethane foam and a process for the production of tufted goods with patterned foam backing
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
AU2003247515A1 (en) 2002-06-10 2003-12-22 Wyeth Novel formate salt of o-desmethyl-venlafaxine
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物

Also Published As

Publication number Publication date
SV2005002008A (es) 2005-11-04
EP2052717A1 (en) 2009-04-29
JP2007520553A (ja) 2007-07-26
IL177052A0 (en) 2006-12-10
NO20063963L (no) 2006-09-05
CN1917860A (zh) 2007-02-21
KR20060132891A (ko) 2006-12-22
ECSP066827A (es) 2006-11-24
PE20050771A1 (es) 2005-11-15
AR050230A1 (es) 2006-10-11
US20050175698A1 (en) 2005-08-11
RU2006127437A (ru) 2008-03-20
SG149894A1 (en) 2009-02-27
WO2005077340A1 (en) 2005-08-25
AU2005212166A1 (en) 2005-08-25
PA8622601A1 (es) 2005-10-28
CA2554559A1 (en) 2005-08-25
EP1711167A1 (en) 2006-10-18
ZA200606526B (en) 2010-03-31
BRPI0507372A (pt) 2007-07-10
CR8535A (es) 2006-12-07

Similar Documents

Publication Publication Date Title
TWI495491B (zh) 可壓製包被的藥物組合物和片劑以及製造方法
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP4971159B2 (ja) プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
JP4789806B2 (ja) パントプラゾール多粒子処方
TW200528092A (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
RU2590979C2 (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
CN103025317B (zh) 钠布啡类制剂及其用途
JP2000515871A (ja) トラマドール複式ユニット製剤
TW200942273A (en) Drug delivery systems comprising weakly basic drugs and organic acids
EP2405900A2 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
EP2385823A1 (en) Dual release pharmaceutical suspension
JP2009501233A (ja) バイオアベイラビリティーの高いｏ−デスメチルベンラファキシンスクシネートの経口用遅延放出投薬形態
US9833436B2 (en) Method of preparing drug agglomerate
CN103315965A (zh) 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法
TW200848056A (en) Solid dispersion of a neurokinin antagonist
WO2015055130A2 (zh) 一种长效缓释微丸及其制备方法
WO2014040548A1 (zh) 一种美托洛尔的缓释药物及其制备方法
JP2007520553A5 (https=)
WO2012098499A1 (en) Solid molecular dispersion
CN106822907B (zh) 一种含消旋卡多曲的双相释放制剂及其制备方法
CN114901256A (zh) 具有持续释放褪黑激素小丸的剂型
WO2011096953A1 (en) Oral antidepressant formulation with reduced excipient load
JP2014101332A (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
MXPA06008933A (en) Multiparticulate o-desmethylvenlafaxine salts and uses thereof
CN106265528A (zh) 制备药物凝集体的方法